These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1301 related items for PubMed ID: 25970007

  • 1. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ, Luheshi NM, Beyaz N, Davies GC, Legg JW, Wu H, Dall'Acqua WF, Tsui P.
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [Abstract] [Full Text] [Related]

  • 2. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG.
    Blood; 1997 Dec 01; 90(11):4485-92. PubMed ID: 9373259
    [Abstract] [Full Text] [Related]

  • 3. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
    Brandsma AM, Ten Broeke T, Nederend M, Meulenbroek LA, van Tetering G, Meyer S, Jansen JH, Beltrán Buitrago MA, Nagelkerke SQ, Németh I, Ubink R, Rouwendal G, Lohse S, Valerius T, Leusen JH, Boross P.
    Cancer Immunol Res; 2015 Dec 01; 3(12):1316-24. PubMed ID: 26407589
    [Abstract] [Full Text] [Related]

  • 4. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR.
    Methods; 2014 Jan 01; 65(1):114-26. PubMed ID: 23872058
    [Abstract] [Full Text] [Related]

  • 5. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G, Heijnen IA, Cuomo E, van der Linden J, Boel E, van de Winkel JG, Logtenberg T.
    Cancer Res; 1999 Nov 15; 59(22):5778-84. PubMed ID: 10582699
    [Abstract] [Full Text] [Related]

  • 6. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
    Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ.
    MAbs; 2015 Nov 15; 7(3):494-504. PubMed ID: 25933349
    [Abstract] [Full Text] [Related]

  • 7. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
    Brandsma AM, Bondza S, Evers M, Koutstaal R, Nederend M, Jansen JHM, Rösner T, Valerius T, Leusen JHW, Ten Broeke T.
    Front Immunol; 2019 Nov 15; 10():704. PubMed ID: 31031746
    [Abstract] [Full Text] [Related]

  • 8. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A, Bern M, Foss S, Bratlie DB, Moen A, Gunnarsen KS, Aase A, Michaelsen TE, Sandlie I, Andersen JT.
    J Immunol; 2015 Jun 01; 194(11):5497-508. PubMed ID: 25904551
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
    Li B, Xu L, Tao F, Xie K, Wu Z, Li Y, Li J, Chen K, Pi C, Mendelsohn A, Larrick JW, Gu H, Fang J.
    Oncotarget; 2017 Jun 13; 8(24):39356-39366. PubMed ID: 28454118
    [Abstract] [Full Text] [Related]

  • 10. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
    Duchemin M, Khamassi M, Xu L, Tudor D, Bomsel M.
    Front Immunol; 2018 Jun 13; 9():244. PubMed ID: 29651286
    [Abstract] [Full Text] [Related]

  • 11. IgA EGFR antibodies mediate tumour killing in vivo.
    Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, van Rooijen N, Bleeker WK, Parren PW, van de Winkel JG, Valerius T, Leusen JH.
    EMBO Mol Med; 2013 Aug 13; 5(8):1213-26. PubMed ID: 23918228
    [Abstract] [Full Text] [Related]

  • 12. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
    Braster R, O'Toole T, van Egmond M.
    Methods; 2014 Jan 01; 65(1):28-37. PubMed ID: 23811299
    [Abstract] [Full Text] [Related]

  • 13. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
    van Egmond M, van Spriel AB, Vermeulen H, Huls G, van Garderen E, van de Winkel JG.
    Cancer Res; 2001 May 15; 61(10):4055-60. PubMed ID: 11358825
    [Abstract] [Full Text] [Related]

  • 14. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M, Wallace PK, Keler T, Deo YM, Akewanlop C, Hayes DF.
    Breast Cancer Res Treat; 1999 Feb 15; 53(3):199-207. PubMed ID: 10369066
    [Abstract] [Full Text] [Related]

  • 15. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM, Sundarapandiyan K, Keler T, Wallace PK, Graziano RF.
    J Immunol; 1998 Feb 15; 160(4):1677-86. PubMed ID: 9469424
    [Abstract] [Full Text] [Related]

  • 16. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B, Dechant M, van Egmond M, Tutt AL, Sundarapandiyan K, Graziano RF, Repp R, Kalden JR, Gramatzki M, Glennie MJ, van de Winkel JG, Valerius T.
    J Immunol; 2000 Nov 15; 165(10):5954-61. PubMed ID: 11067958
    [Abstract] [Full Text] [Related]

  • 17. The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy.
    Chan C, Cabanes NC, Jansen JHM, Guillaume J, Nederend M, Passchier EM, Gómez-Mellado VE, Peipp M, Boes M, van Tetering G, Leusen JHW.
    Cancer Immunol Immunother; 2024 Oct 03; 73(12):238. PubMed ID: 39358557
    [Abstract] [Full Text] [Related]

  • 18. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R, Shimomura I, Konno S, Ito A, Masakari Y, Orimo R, Taki S, Arai K, Ogata H, Okada M, Furumoto S, Onitsuka M, Omasa T, Hayashi H, Katayose Y, Unno M, Kudo T, Umetsu M, Kumagai I.
    MAbs; 2014 Oct 03; 6(5):1243-54. PubMed ID: 25517309
    [Abstract] [Full Text] [Related]

  • 19. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18).
    van Egmond M, van Vuuren AJ, Morton HC, van Spriel AB, Shen L, Hofhuis FM, Saito T, Mayadas TN, Verbeek JS, van de Winkel JG.
    Blood; 1999 Jun 15; 93(12):4387-94. PubMed ID: 10361137
    [Abstract] [Full Text] [Related]

  • 20. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G.
    Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA, Prang NS.
    Mol Immunol; 2006 Mar 15; 43(8):1183-93. PubMed ID: 16102830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 66.